These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37750695)

  • 1. Safety and tolerability of tedizolid as oral treatment for bone and joint infections.
    Miller LG; Flores EA; Launer B; Lee P; Kalkat P; Derrah K; Agrawal S; Schwartz M; Steele G; Kim T; Kuvhenguhwa MS
    Microbiol Spectr; 2023 Sep; 11(5):e0128223. PubMed ID: 37750695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of tedizolid and comparator agents against Gram-positive pathogens responsible for bone and joint infections.
    Ract P; Piau-Couapel C; Compain F; Auzou M; Michon J; Cattoir V
    J Med Microbiol; 2017 Oct; 66(10):1374-1378. PubMed ID: 28920854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).
    Carvalhaes CG; Sader HS; Flamm RK; Mendes RE
    J Antimicrob Chemother; 2019 Jul; 74(7):1928-1933. PubMed ID: 30932152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019).
    Pfaller M; Mendes RE; Streit JM; Carvalhaes CG
    Diagn Microbiol Infect Dis; 2022 Dec; 104(4):115804. PubMed ID: 36170792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
    Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
    J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
    Fang E; Muñoz KA; Prokocimer P
    Am J Ther; 2017; 24(2):e227-e233. PubMed ID: 27941424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded Staphylococcus aureus in the bone and joint infection setting.
    Abad L; Tafani V; Tasse J; Josse J; Chidiac C; Lustig S; Ferry T; Diot A; Laurent F; Valour F
    J Antimicrob Chemother; 2019 Mar; 74(3):625-632. PubMed ID: 30517641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of thrombocytopenia caused by linezolid with scheduled sequential tedizolid use in patients with vertebral osteomyelitis by antibiotic resistant Gram-positive organisms.
    Ueda T; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Iijima K; Ikeuchi H; Uchino M; Kimura T; Takesue Y
    J Infect Chemother; 2022 Jul; 28(7):1023-1028. PubMed ID: 35477667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Tolerability of More than Six Days of Tedizolid Treatment.
    Mensa Vendrell M; Tasias Pitarch M; Salavert Lletí M; Calabuig Muñoz E; Morata Ruiz L; Castells Lao G; López Suñé E; Mensa Pueyo J; Oltra Sempere MR; Pedro-Botet Montoya ML; Isernia V; Reynaga Sosa EA; Moreno Nuñez L; Pasquau Liaño J; Sequera Arquelladas S; Yuste Ara JR; Soriano Viladomiu A
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32312777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
    Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age.
    Arrieta AC; Ang JY; Espinosa C; Fofanov O; Tøndel C; Chou MZ; De Anda CS; Kim JY; Li D; Sabato P; Sears PS; Bradley JS
    Pediatr Infect Dis J; 2021 Apr; 40(4):317-323. PubMed ID: 33710976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
    Ortiz-Covarrubias A; Fang E; Prokocimer PG; Flanagan SD; Zhu X; Cabré-Márquez JF; Tanaka T; Passarell J; Fiedler-Kelly J; Nannini EC
    Braz J Infect Dis; 2016; 20(2):184-92. PubMed ID: 26859064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs.
    Benavent E; Morata L; Escrihuela-Vidal F; Reynaga EA; Soldevila L; Albiach L; Pedro-Botet ML; Padullés A; Soriano A; Murillo O
    Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33429902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.